Well-Funded Chinese Venture Races To Clinic Amid Reviving CNS Interest

 
• By Dexter Jie Yan

SciNeuro’s latest in-licensing deals include three assets for major neurodegenerative diseases from Lilly and Mabylon, but the Chinese bioventure is looking beyond the shopping spree at what it sees as outstanding CNS needs.

SciNeuro races to clinical trials
Proof-of-concept will be at forefront of ScieNeuro's upcoming trials • Source: Alamy

More from China

More from Focus On Asia